The funding will help 4G Clinical accelerate its global expansion. Here are the top-line bullets you need to know.
4G Clinical, a clinical trial software company, has raised $230M in a Series D with participation from Goldman Sachs Asset Management.
HOW’S THE COMPANY PERFORMING?
- Massachusetts-based 4G Clinical is a randomization and trial supply management (RTSM) software provider. It enables biotech and pharma companies to prevent stockouts and reduce drug waste.
- The company says it has 100 customers and is running 252 studies.
- The company reportedly grew its revenue by 110% in 2020, with Covid-related research representing 10% of all projects.
- Headquartered in the US, 4G Clinical also has offices in Tokyo, Tel Aviv, Amsterdam, Dublin, Basel, and Cologne.
Source: 4G Clinical
WHY DOES THE MARKET MATTER?
- The global clinical trials market is projected to grow at a CAGR of 5.7% and reach a value of $69.5B by 2028, according to Grand View Research.
- The use of AI in healthcare has shown increasing potential in saving time as it brings drugs to markets faster by identifying accurate patients for clinical trials.
Want to see more research? Join a demo of the CB Insights platform.
If you’re already a customer, log in here.
